期刊
SCIENCE
卷 346, 期 6212, 页码 945-949出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1253735
关键词
-
资金
- NIH [T32GM007753, P01CA163222, R01AR043369, R01CA150226]
- Melanoma Research Alliance, the U.S.-Israel Binational Science Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Melanoma, the deadliest form of skin cancer, is an a ressive disease that is rising in incidence. Although melanoma is a historically treatment-resistant malignancy, in recent years unprecedented breakthroughs in targeted therapies and immunotherapies have revolutionized the standard of care for patients with advanced disease. Here, we provide an overview of recent developments in our understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment. In addition, we review benefits and limitations of current therapies and look ahead to continued progress in melanoma prevention and therapy. Remarkable achievements in the field have already produced a paradigm shift in melanoma treatment: Metastatic melanoma, once considered incurable, can now be treated with potentially curative rather than palliative intent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据